Summer B Gibson1, Jonathan M Downie2, Spyridoula Tsetsou1, Julie E Feusier1, Karla P Figueroa1, Mark B Bromberg1, Lynn B Jorde1, Stefan M Pulst1. 1. From the Departments of Neurology (S.B.G., S.T., K.P.F., M.B.B., S.M.P.) and Human Genetics (J.M.D., J.E.F., L.B.J.), University of Utah School of Medicine, Salt Lake City. 2. From the Departments of Neurology (S.B.G., S.T., K.P.F., M.B.B., S.M.P.) and Human Genetics (J.M.D., J.E.F., L.B.J.), University of Utah School of Medicine, Salt Lake City. jonathan.downie@hsc.utah.edu.
Abstract
OBJECTIVE: To estimate the genetic risk conferred by known amyotrophic lateral sclerosis (ALS)-associated genes to the pathogenesis of sporadic ALS (SALS) using variant allele frequencies combined with predicted variant pathogenicity. METHODS: Whole exome sequencing and repeat expansion PCR of C9orf72 and ATXN2 were performed on 87 patients of European ancestry with SALS seen at the University of Utah. DNA variants that change the protein coding sequence of 31 ALS-associated genes were annotated to determine which were rare and deleterious as predicted by MetaSVM. The percentage of patients with SALS with a rare and deleterious variant or repeat expansion in an ALS-associated gene was calculated. An odds ratio analysis was performed comparing the burden of ALS-associated genes in patients with SALS vs 324 normal controls. RESULTS: Nineteen rare nonsynonymous variants in an ALS-associated gene, 2 of which were found in 2 different individuals, were identified in 21 patients with SALS. Further, 5 deleterious C9orf72 and 2 ATXN2 repeat expansions were identified. A total of 17.2% of patients with SALS had a rare and deleterious variant or repeat expansion in an ALS-associated gene. The genetic burden of ALS-associated genes in patients with SALS as predicted by MetaSVM was significantly higher than in normal controls. CONCLUSIONS: Previous analyses have identified SALS-predisposing variants only in terms of their rarity in normal control populations. By incorporating variant pathogenicity as well as variant frequency, we demonstrated that the genetic risk contributed by these genes for SALS is substantially lower than previous estimates.
OBJECTIVE: To estimate the genetic risk conferred by known amyotrophic lateral sclerosis (ALS)-associated genes to the pathogenesis of sporadic ALS (SALS) using variant allele frequencies combined with predicted variant pathogenicity. METHODS: Whole exome sequencing and repeat expansion PCR of C9orf72 and ATXN2 were performed on 87 patients of European ancestry with SALS seen at the University of Utah. DNA variants that change the protein coding sequence of 31 ALS-associated genes were annotated to determine which were rare and deleterious as predicted by MetaSVM. The percentage of patients with SALS with a rare and deleterious variant or repeat expansion in an ALS-associated gene was calculated. An odds ratio analysis was performed comparing the burden of ALS-associated genes in patients with SALS vs 324 normal controls. RESULTS: Nineteen rare nonsynonymous variants in an ALS-associated gene, 2 of which were found in 2 different individuals, were identified in 21 patients with SALS. Further, 5 deleterious C9orf72 and 2 ATXN2 repeat expansions were identified. A total of 17.2% of patients with SALS had a rare and deleterious variant or repeat expansion in an ALS-associated gene. The genetic burden of ALS-associated genes in patients with SALS as predicted by MetaSVM was significantly higher than in normal controls. CONCLUSIONS: Previous analyses have identified SALS-predisposing variants only in terms of their rarity in normal control populations. By incorporating variant pathogenicity as well as variant frequency, we demonstrated that the genetic risk contributed by these genes for SALS is substantially lower than previous estimates.
Authors: Kevin P Kenna; Russell L McLaughlin; Susan Byrne; Marwa Elamin; Mark Heverin; Elaine M Kenny; Paul Cormican; Derek W Morris; Colette G Donaghy; Daniel G Bradley; Orla Hardiman Journal: J Med Genet Date: 2013-07-23 Impact factor: 6.318
Authors: Peter D Stenson; Matthew Mort; Edward V Ball; Katy Shaw; Andrew Phillips; David N Cooper Journal: Hum Genet Date: 2014-01 Impact factor: 4.132
Authors: Adam Auton; Lisa D Brooks; Richard M Durbin; Erik P Garrison; Hyun Min Kang; Jan O Korbel; Jonathan L Marchini; Shane McCarthy; Gil A McVean; Gonçalo R Abecasis Journal: Nature Date: 2015-10-01 Impact factor: 49.962
Authors: Frank W Pun; Bonnie Hei Man Liu; Xi Long; Hoi Wing Leung; Geoffrey Ho Duen Leung; Quinlan T Mewborne; Junli Gao; Anastasia Shneyderman; Ivan V Ozerov; Ju Wang; Feng Ren; Alexander Aliper; Evelyne Bischof; Evgeny Izumchenko; Xiaoming Guan; Ke Zhang; Bai Lu; Jeffrey D Rothstein; Merit E Cudkowicz; Alex Zhavoronkov Journal: Front Aging Neurosci Date: 2022-06-28 Impact factor: 5.702
Authors: Marie Ryan; Mark Heverin; Mark A Doherty; Nicola Davis; Emma M Corr; Alice Vajda; Niall Pender; Russell McLaughlin; Orla Hardiman Journal: Neurol Genet Date: 2018-05-18
Authors: Mark W Kankel; Anindya Sen; Lei Lu; Marina Theodorou; Douglas N Dimlich; Alexander McCampbell; Christopher E Henderson; Neil A Shneider; Spyros Artavanis-Tsakonas Journal: Genetics Date: 2020-04-28 Impact factor: 4.562
Authors: Domenico Di Curzio; Mamneet Gurm; Matthew Turnbull; Marie-Josée Nadeau; Breanna Meek; Julia D Rempel; Samuel Fineblit; Michael Jonasson; Sherry Hebert; Jennifer Ferguson-Parry; Renée N Douville Journal: Cells Date: 2020-06-30 Impact factor: 6.600
Authors: Kristi L Russell; Jonathan M Downie; Summer B Gibson; Spyridoula Tsetsou; Matthew D Keefe; Jerry A Duran; Karla P Figueroa; Mark B Bromberg; L Charles Murtaugh; Joshua L Bonkowsky; Stefan M Pulst; Lynn B Jorde Journal: Neurology Date: 2021-06-16 Impact factor: 11.800
Authors: Emilio Geijo-Barrientos; Carlos Pastore-Olmedo; Pedro De Mingo; Miguel Blanquer; Joaquín Gómez Espuch; Francisca Iniesta; Natalia García Iniesta; Ana García-Hernández; Carlos Martín-Estefanía; Laura Barrios; José M Moraleda; Salvador Martínez Journal: Front Neurosci Date: 2020-03-24 Impact factor: 4.677